Driving Sustainability in Clinical Supply Chains: ADAllen Pharma’s Latest Carbon Footprint & Carbon Reduction Plan
In a clinical trials landscape where environmental performance increasingly matters to sponsors, regulators and partners, ADAllen Pharma has taken a major step forward by publishing its 2026 Carbon Footprint Report and Carbon Reduction Plan. These in-depth reports benchmark the company’s greenhouse gas (GHG) emissions, highlight sustainability priorities, and outline clear strategies to reduce carbon intensity across operations and value chains. For pharmaceutical organisations looking for responsible supply partners, this latest environmental reporting reinforces ADAllen Pharma’s leadership and commitment to decarbonisation.
Comprehensive Carbon Footprint Transparency
The 2026 Carbon Footprint Report for ADAllen Pharma provides an independently quantified greenhouse gas inventory covering emissions from 1 January to 31 December 2024. The inventory follows the globally recognised Greenhouse Gas Protocol Corporate and Value Chain Standards, ensuring a high level of transparency and comparability with other organisations.
Across this baseline year, total emissions were reported at 45 tCO₂e, capturing both direct operations and broader supply chain impacts. The breakdown shows:
- Scope 1 (direct) emissions are near zero, thanks to an entirely electric company vehicle fleet and electric heating systems.
- Scope 2 (indirect electricity) emissions remain modest, reflecting conservative energy usage practices.
- Scope 3 (value chain) emissions dominate the footprint, with upstream and downstream transport, purchased goods and services, and distribution comprising the lion’s share of the total.
This level of detail not only sets a robust baseline for future improvements but also demonstrates the complexity of carbon emissions in modern clinical supply operations — where logistics, transportation and procurement contribute substantially to environmental impact.
A Strategic Carbon Reduction Plan
Building on this baseline, the 2026 Carbon Reduction Plan presents ADAllen Pharma’s short- and long-term emissions reduction strategy. The plan adheres to the UK Government’s PPN 06/21 reporting framework and Institute best practices for carbon reporting.
Key highlights from the plan include:
- Zero Scope 1 emissions moving forward, achieved through electrification of company vehicles and reliance on electric infrastructure.
- Concrete targets for Scope 2 and Scope 3 emissions, aligned with broader industry expectations for decarbonisation in the pharmaceutical supply space.
- A focus on reducing upstream transport emissions and downstream distribution, which together represent the largest share of reported value chain emissions.
- Inclusion of employee commuting, waste generation, and purchasing behaviour within emissions monitoring and future reduction efforts.
These steps support ADAllen Pharma’s ongoing environmental policy goals — including transitioning to renewable electricity, enhancing sustainable logistics, and engaging supply partners in shared sustainability objectives, as outlined in the company’s published environmental policy.
Why This Matters for Clinical Trial Sponsors
For pharmaceutical companies, contract research organisations (CROs) and healthcare sponsors demanding increasingly rigorous environmental standards from suppliers, ADAllen Pharma’s carbon reporting underscores a commitment to responsible clinical supply chain stewardship. The transparency of emissions data and the publication of forward-looking reduction targets align with emerging expectations across the life sciences sector for sustainability benchmarking and carbon accountability.
By integrating sustainability into its core reporting framework, ADAllen Pharma not only enhances its corporate responsibility credentials but also supports client organisations in meeting their own environmental, social, and governance (ESG) goals.
Partnering with ADAllen Pharma for Sustainable Clinical Supplies
As a UK specialist in sourcing licensed comparator drugs, biosimilars and ancillary products for clinical trials — alongside services like expert project management, cold chain storage, and logistics solutions — ADAllen Pharma is uniquely positioned to support environmentally conscious clinical programmes. Explore the full suite of services designed to meet every clinical trial need at the ADAllen Pharma Services page.
In a sector where operational excellence intersects with sustainability, ADAllen Pharma’s latest reports are a testament to measurable action and strategic planning, setting a new benchmark for environmentally responsible clinical supply partners.
Please download our latest Carbon footprint and Carbon Reduction Plan reports, for more information.ESG
